• Tuesday, April 25, 2023 @ 7:00 am

Some major achievements of Swiss biotech innovation…

  • 1998 Monoclonal antibodies Trastuzumab
    Herceptin, Roche, breast cancer
  • 1998 Interferon beta-1a
    Rebif, Serono, multiple sclerosis
  • 2001 Bosentan
    Tracleer, Actelion, pulmonary arterial hypertension (PAH)
  • 2003 Kinase inhibitors Imatinib
    Gleevec, Novartis, cancer
  • 2013 CRISPR-Cas9 gene editing
    CRISPR Therapeutics using technology to treat genetic diseases
  • 2013 Humanized anti-CD20 monoclonal antibody Obinutuzumab
    Gazyva, Glycart/Roche, chronic lymphocytic leukaemia
  • 2017 CAR-T cell therapy Tisagenlecleucel
    Kymriah, Novartis, leukaemia
  • 2019 Humanized single chain antibody anti-VEGF Brolucizumab
    Beovu, Esbatech/Novartis, wet-AMD
  • 2019 Gene therapy Onasemnogene abeparvovec-xioi
    Zolgensma, Novartis, paediatric spinal muscular atrophy (SMA)
  • 2021 Aducanumab
    Aduhelm, Neuroimmune/Biogen, Alzheimer’s disease
  • 2023 DDM Genomics and Multimodal platform
    SOPHiA GENETICS hits milestone of One Million Genomic Profiles analyzed by the SOPHiA DDM™ platform

Most of these highlights were achieved in international collaboration and benefit patients around the world. They do not represent a comprehensive list but rather a selection that emphasizes the diversity of modalities that have been developed over time and the broad range of medical needs they help to address.

Keep browsing

You may also be interested in